About Penta
Who we are
Diversity and Inclusion
Penta ID Network
Penta Foundation Italy
Penta Foundation UK
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Call for services
Diversity & Inclusion
Brighter Future Award
Archivio
PENTA guidelines for the use of antiretroviral therapy 2004
72-week follow-up of HAART started in infants aged less than 3 months: CD4, viral load and drug resistance outcomes in the PENTA 7 study
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens